ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,467.89
      -0.10%
      US Tech 100
      19,268.00
      0.05%
      Dow Jones
      39,123.46
      -0.03%
      Brent Oil
      84.885
      -0.14%
      Bitcoin
      63,751.81
      -1.65%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Sanofi (SAN)

      7. Sanofi (SAN) News

      SAN

      Sanofi (SAN)

      Sanofi
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:SAN
      DateTimeSourceHeadlineSymbolCompany
      06/21/20243:30AMGlobeNewswire Inc.Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de SanofiEU:SANSanofi
      06/21/20243:30AMGlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
      06/21/20243:30AMGlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
      06/21/20241:00AMGlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
      06/21/20241:00AMGlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
      06/21/20241:00AMGlobeNewswire Inc.Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilieEU:SANSanofi
      06/20/20248:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en AfriqueEU:SANSanofi
      06/20/20248:00AMGlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
      06/20/20248:00AMGlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
      06/12/20242:19PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – May 2024EU:SANSanofi
      06/12/20242:19PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024EU:SANSanofi
      06/03/20244:15PMGlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
      06/03/20244:15PMGlobeNewswire Inc.Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]EU:SANSanofi
      06/03/20244:15PMGlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
      05/31/20246:00AMGlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
      05/31/20246:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salariéEU:SANSanofi
      05/31/20246:00AMGlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
      05/30/20249:01AMGlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
      05/30/20249:01AMGlobeNewswire Inc.Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.EU:SANSanofi
      05/30/20249:01AMGlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
      05/27/20241:00AMGlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
      05/27/20241:00AMGlobeNewswire Inc.Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantationEU:SANSanofi
      05/27/20241:00AMGlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
       Showing the most relevant articles for your search:EU:SAN